Results 281 to 290 of about 264,642 (338)

PD-L1 Expression in Pancreatic Cancer [PDF]

Journal of the National Cancer Institute, 2017
openaire   +3 more sources

Overcoming EGFR‐Mediated Dendritic Cell Dysfunction to Enhance Anti‐tumor Immunity in EGFR‐Mutant NSCLC by Precisely Targeting CD73 With pH‐responsive Nanocarriers

Advanced Science, EarlyView.
EGFR mutations drive ERK/c‐Jun–mediated transcriptional activation of CD73, elevating adenosine levels and fostering an immunosuppressive TME by impairing DC maturation and CD8⁺ T cell priming. The pH‐responsive nanodrug F127ZIF‐8AB680 selectively inhibits CD73, normalizes adenosine metabolism, and re‐establishes effective anti‐tumor immunity ...
Xiaoling Shang, Xudong Geng, Zixu Wang, Shumin Yuan, Shanshan Ding, Ni Liu, Xinchun Ma, Xuan Sun, Huimin Wang, Ying Sun, Xun Qu, Guangwen Ren, Yong Qiang Li, Xiuwen Wang, Yanguo Liu   +14 more
wiley   +1 more source

PD-L1 and BCG response prediction [PDF]

Nature Reviews Urology, 2019
openaire   +3 more sources

Sulfur Vacancy‐Engineered Co9S8‐Ni3S4 Heterostructure as a Hydrogen Spillover Catalyst for Efficient Alkaline Water Splitting

Advanced Science, EarlyView.
A sulfur vacancy‐engineered Co9S8‐Ni3S4 hollow heterostructure is rationally designed to trigger hydrogen spillover, where vacancy‐mediated interfacial modulation enables efficient H migration and accelerates HER kinetics. Abstract Developing highly efficient and robust catalysts based on earth‐abundant materials for electrochemical water splitting ...
Shoushuang Huang, Tianyu Jin, Jie Zhang, Yong Jiang, Jiwen Hu, Hejingying Niu, Amene Naseri, Kajsa Uvdal, Zhangjun Hu, Jiujun Zhang   +9 more
wiley   +1 more source

PD-L1 importance in malignancies comprehensive insights into the role of PD-L1 in malignancies: from molecular mechanisms to therapeutic opportunities. [PDF]

Clin Exp Med
Soltani M, Abbaszadeh M, Fouladseresht H, Sullman MJM, Eskandari N.   +4 more
europepmc   +1 more source

Emerging Nanozyme Strategies for Precision Breast Cancer Treatment

Advanced Science, EarlyView.
Different types of nanozymes‐mediated chemotherapy, photothermal therapy, immunotherapy, and multiple combined therapies for the effective treatment of breast cancer. Abstract Breast cancer, the most common malignant tumor among women worldwide, poses a significant challenge to public health due to its high incidence and mortality rates.
Jian Zang, Zhaozhou Ren, Haibo Wang, Xing Yang, Yang Song, Jun Liao, Xiaoying Li   +6 more
wiley   +1 more source

Clinical evaluation of a novel-developed clone 3E2 for the detection of PD-L1 expression status in lung adenocarcinoma. [PDF]

BMC Cancer
Qu F, Wang J, Zhao Q, Jiang H, Zhong X, Xu Q, Yang X, Hu L, Zhang Z, Zheng Y.   +9 more
europepmc   +1 more source

Spatial Transcriptomics and snRNA‐seq Expose CAF Niches Orchestrating Dual Stromal‐Immune Barriers in Hepatocellular Carcinoma

Advanced Science, EarlyView.
HmmyCAFs may form a triple immunosuppressive niche: possibly secrete ECM (POSTN, etc.) as physical barriers to block CD8⁺ T cells, induce CD8⁺ T exhaustion via those molecules, and use HIF‐1α‐driven metabolism to create acidic, nutrient‐poor microenvironments that suppress T cells.
Yingxue Li, Changxiang Huan, Haoting Sun, Wei Zhang, Zhen Guo, Chuanyu Li, Jia Yao, Zhiqi Zhang, Shizhe Yu, Qiongzhu Dong, Lunxiu Qin, Jinze Li, Lianqun Zhou   +12 more
wiley   +1 more source

Spotlight on nuclear PD-L1 in ovarian cancer chemoresistance: hidden but mighty. [PDF]

Front Immunol
Asare-Werehene M, Zaker A, Tripathi S, Communal L, Carmona E, Mes-Masson AM, Tsang BK, Mer A.   +7 more
europepmc   +1 more source

Engineering Metal‐Organic‐Framework‐Based STING Nanoagonists for PROTAC‐Enhanced Cancer Chemo‐Metalloimmunotherapy

Advanced Science, EarlyView.
Schematic overview of PROTAC‐enhanced chemo‐metalloimmunotherapy, integrating senescence induction, multi‐modal STING pathway activation, PD‐L1 blockade, and immune amplification via coordinated PROTACs, metal ions, and chemotherapy to elicit robust antitumor immunity and circumvent immune evasion.
Zhenzhen Chen, Zhe Feng, Siyuan Wang, Jingjing Zhang   +3 more
wiley   +1 more source